LeMaitre Vascular, Inc. (LHU.F)

75,50 +1,50 (+2,03%) Alla chiusura: 08:12AM CEST

LeMaitre Vascular, Inc.

63 Second Avenue
Burlington, MA 01803
United States
781 221 2266
https://www.lemaitre.com

Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 614

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. George W. LeMaitre	Chairman & CEO	1,04M	1,22M	1965
Mr. David B. Roberts	President & Director	591,54k	1,16M	1964
Mr. Joseph P. Pellegrino Jr.	CFO, Secretary & Director	527,56k	N/D	1965
Mr. Trent G. Kamke	Senior Vice President of Operations	414,99k	74,94k	1971
Dr. George D. LeMaitre	Founder and Chairman of Scientific Advisory Board	110,4k	N/D	1934
Ms. Kimberly L. Cieslak	Vice President of Marketing	N/D	N/D	1973
Mr. Daniel J. Mumford	Senior Director of Human Resources	N/D	N/D	1982
Mr. Jonathan W. Ngau	Senior Vice President of Information Technology	N/D	N/D	1974
Mr. Maik D. Helmers	Senior Vice President of Sales – Central Europe	N/D	N/D	1974
Mr. Ryan H. Connelly	Senior Vice President of Advanced Manufacturing Engineering	N/D	N/D	1977

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di LeMaitre Vascular, Inc. al 1 giugno 2024 è 6. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.